Zobrazeno 1 - 10
of 328
pro vyhledávání: ''
Autor:
Hélène M. Faessel, Xiaofei Zhou, Karthik Venkatakrishnan, Douglas V. Faller, Farhad Sedarati, Diane R. Mould
Publikováno v:
British Journal of Clinical Pharmacology
Aims A population pharmacokinetic (PK) analysis was conducted to quantify the impact of patient-specific and concurrent medication factors on pevonedistat PK. Methods Data were pooled from 6 clinical studies consisting of 335 patients with solid tumo
Publikováno v:
Br J Clin Pharmacol
Aims Chlorzoxazone is the paradigm marker substrate for CYP2E1 phenotyping in vivo. Because at the commonly used milligram doses (250-750 mg) chlorzoxazone acts as an inhibitor of the CYP3A4/5 marker substrate midazolam, previous attempts failed to c
Autor:
Monia Guidi, Anaïs Glatard, Chantal Csajka, Perrine Courlet, Catia Marzolini, Susana Alves Saldanha, Laurent A. Decosterd, Thierry Buclin, Matthias Cavassini, Chin B. Eap
Publikováno v:
Br J Clin Pharmacol
AIMS: The aims of this study were to characterize escitalopram pharmacokinetic profile, to identify factors influencing drug exposure, notably drug–drug interactions with antiretrovirals, and to simulate expected exposure under standard dosage regi
Publikováno v:
British Journal of Clinical Pharmacology
Aims Quizartinib is an oral, highly potent and selective next-generation FMS-like tyrosine kinase 3 (FLT3) inhibitor under investigation in patients with FLT3-internal tandem duplication-mutated acute myeloid leukaemia. This drug-drug interaction stu
Autor:
Katy P Moore, Cyril Llamoso, Elsa Myers, Mindy Magee, Heather Sevinsky, Susan Lubin, Peter Ackerman, Ming Chang
Publikováno v:
British Journal of Clinical Pharmacology
Aims Regional human immunodeficiency virus (HIV) prevalence rates are high in people with history of injection drug use, including those managed with maintenance opioids. Fostemsavir (FTR) is an oral prodrug of temsavir, a first-in-class attachment i
Publikováno v:
Br J Clin Pharmacol
AIMS: To investigate presence or absence of clinically relevant drug interactions (pharmacokinetic and safety/tolerability) of OBE022 with standard‐of‐care medicines for preterm labour, enabling coadministration and further clinical development.
Autor:
Antonia Brings, David Czock, Marie-Louise Lehmann, Johanna Weiss, Kathrin I. Foerster, Walter E. Haefeli, Jürgen Burhenne
Publikováno v:
Br J Clin Pharmacol
Aims Rivaroxaban exposure is considerably increased by drugs that are combined P-glycoprotein (P-gp) and strong cytochrome P450 (CYP) 3A inhibitors (e.g. ketoconazole). The aim of the present study was to investigate the effects of the potent P-gp in
Autor:
Kyriakos P. Papadopoulos, Zhengping Wang, R. Donald Harvey, Yang Xu, Alain C. Mita, Ying Ou, Dawn E. Pinchasik, Apostolia Maria Tsimberidou, Lia Gore, Richard E. Cutler
Publikováno v:
British Journal of Clinical Pharmacology. 85:530-539
Aims Oprozomib is an oral, second-generation, irreversible proteasome inhibitor currently in clinical development for haematologic malignancies, including multiple myeloma and other malignancies. Oprozomib is a rare example of a small molecule drug t
Publikováno v:
Br J Clin Pharmacol
Publikováno v:
British Journal of Clinical Pharmacology. 83:2821-2830
AIMS The aims of the present study were to examine the prevalence of high-risk prescribing (HRP) in community-dwelling adults in Ireland from 2011-2015 using consensus-validated indicators, factors associated with HRP, and the variation in HRP betwee